Defining the transcriptomic identity of malignant cells is challenging in the absence of surface markers that distinguish cancer clones from one another, or from admixed non-neoplastic cells. To address this challenge, here we developed Genotyping of Transcriptomes (GoT), a method to integrate genotyping with high-throughput droplet-based singlecell RNA sequencing. We apply GoT to profile 38,290 CD34
Somatic mutations underlie the development of clonal outgrowth, malignant transformation 1 and subclonal diversification 2-5 . Nonetheless, clonally derived populations often lack cell-surface markers that distinguish them from normal cells or that can help to distinguish subclones, which limits our ability to link the clonal architecture of malignant populations with transcriptional read-outs. For example, although myeloproliferative neoplasms result from recurrent somatic mutations in CALR, JAK2 and MPL 6, 7 , the mutated clone often represents a subset of bone marrow progenitors that lack distinctive surface markers to distinguish them from non-neoplastic progenitors. Thus, we are unable to study the effect of myeloproliferative neoplasm mutations in the context of the haematopoietic progenitor subtype identity.
Although advanced methods have been developed to capture both transcriptional information and genotype at the single-cell level 8, 9 , these methods often lack the throughput required to study complex systems such as haematopoietic differentiation. Droplet-based sequencing enables the transcriptomic profiling of thousands of cells 10, 11 , and can potentially also provide genotypic information regarding coding mutations (Extended Data Fig. 1a ). However, current methods-by design-provide sequence information for only a short fragment at the transcript end, which limits the ability of these techniques to jointly genotype somatic mutations. To overcome this challenge, we developed GoT to link the genotyping of expressed genes to transcriptional profiling of thousands of single cells. We applied GoT to CD34
+ cells from patients with myeloproliferative neoplasms, which revealed that myeloproliferative neoplasm mutations in haematopoietic progenitor cells do not lead to uniform transcriptional outputs-but instead show a strong dependence on the progenitor cell identity.
Somatic genotyping in droplet scRNA-seq
To link genotypes to single-cell RNA sequencing (scRNA-seq) in high-throughput droplet-based platforms, we modified the 10x Genomics platform to amplify the targeted transcript and locus of interest (Fig. 1a, Extended Data Fig. 1b, c, Methods) . We then investigated amplicon reads for mutational status, and linked the genotype to single-cell gene-expression profiles using shared cell barcodes (Extended Data Fig. 2a, b) . We tested the ability of GoT to comap single-cell genotypes and transcriptomes in a species-mixing experiment, in which mouse cells with a mutant human CALR transgene were mixed with human cells with a wild-type human CALR transgene 12 (Fig. 1b) . Consistent with precision genotyping, the vast majority of cells with transcripts aligned to the mouse genome showed mutant CALR whereas cells with transcripts aligned to the human genome showed wild-type CALR (96.7% of cells matched the expected species) (Fig. 1b, Extended Data Fig. 2c-g ).
CALR mutations have previously been demonstrated to activate MPL (which results in megakaryocytic proliferation) 7, [12] [13] [14] [15] [16] , but how the mutations perturb the early differentiation of haematopoietic stem and progenitor cells (HSPCs) is largely unknown. We therefore applied GoT to CD34
+ bone marrow cells from five patients with CALR-mutated essential thrombocythaemia, who had not been treated
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with disease-modifying therapy at the time of biopsy (Supplementary Table 1 ). CALR genotyping data were available for 16,614 of 18,722 cells (88.7%), compared to only 1.4% by investigation of CALR in the conventional 10x Genomics data (Fig. 1c, .
To investigate the cellular identities of these progenitors, we performed clustering that was agnostic to the genotyping information, based on the transcriptome information alone 17, 18 (Fig. 1d, . The projection of genotypes onto progenitor maps demonstrated that mutated cells involved all CD34
+ stem and progenitor clusters, which is consistent with previous 6 bulk PCR analysis of CALR in CD34 + cell subsets sorted by fluorescence-activated cell sorting (FACS) (Fig. 1e; see Extended Data Fig. 4d , e for validation with an alternative clustering framework 19 ). Notably, mutated cells did not form novel independent clusters, which confirms that scRNA-seq alone cannot distinguish mutant from wild-type cells and demonstrates that CALR mutations in essential thrombocythaemia affect the entire haematopoietic differentiation hierarchy.
Progenitor-specific CALR mutant fitness
Although mutant cells were observed across all progenitor clusters, their frequencies varied between clusters. The frequency of CALRmutated cells was higher in committed myeloid progenitors (Fig. 1f) and especially in megakaryocytic progenitors (MkPs), which are closely associated with the disease phenotype of elevated platelet counts, as compared to uncommitted HSPC clusters across samples (P < 10 −10 , linear mixed model) (Fig. 1g, Extended Data Fig. 5a ). Consistently, pseudotemporal ordering (pseudotime) analysis 20, 21 showed that CALR-mutated cells were enriched in cells at later pseudotime points, compared to wild-type cells (P < 10 −10 , linear mixed model) (Fig. 1h, i, Extended Data Fig. 5b, c) . We orthogonally validated this finding using bulk genomic DNA droplet-based digital polymerase chain reaction (ddPCR), which showed that there was a lower CALR variant allele frequency (VAF) in CD34 +
CD38
− HSPCs compared to CD34 + CD38 + progenitors (P = 0.02, Wilcoxon rank-sum test) (Fig. 1j) . Thus, although CALR mutations arise in uncommitted haematopoietic stem cells (HSCs) and therefore propagate to populate the entire differentiation tree, the effect of CALR mutations on fitness increases with myeloid differentiation (Extended Data Fig. 5d , e).
GoT enables direct comparison of transcriptional programs between mutant and wild-type cells-not only within the same sample, but also within the same progenitor cluster. For example, CALR-mutated progenitors displayed increased expression of genes that are upregulated in ex vivo cultured progenitors from JAK2-mutated essential thrombocythaemia 22 (most significantly in MkP clusters; combined P <10 −10 , Fisher's method) (Fig. 2a, b) , as JAK2 and CALR mutations partially converge through the activation of similar downstream pathways 23 . We therefore reasoned that a progenitor-subtype-specific comparison of cell-cycle gene expression 24 (Supplementary Table 2 ) in mutant versus wild-type cells might reveal whether the lower fitness effect of CALR mutations in HSPCs compared with MkPs stems from differences in cell proliferation. Whereas mutant HSPCs exhibited only a modest increase in cell-cycle gene expression compared to wild type (P = 0.015, Wilcoxon rank-sum test, mean fold change of 1.2, 95% confidence interval, 1.1-1.4), mutant MkPs demonstrated a robust increase in cell-cycle gene expression versus their wild-type counterparts (P = 4.4 × 10 −4
, Wilcoxon rank-sum test, fold change 1.8, 95% confidence interval 1.4-2.8) (Fig. 2c, Extended Data Fig. 6a) . Notably, the degree of increase in cell-cycle gene expression in mutant MkPs correlated with the platelet counts of the patients (Fig. 2d) , which suggests that early progenitor cell characteristics may correlate with clinical phenotypes and has the potential to inform our understanding of patient-to-patient variability that occurs in spite of shared mutated genotypes.
Cell-to-cell variation exists even within progenitor clusters. ) showed no difference in cell-cycle gene expression (Fig. 2f) . These findings further emphasize that the effect of CALR mutations is dependent on cell state, and imparts a greater proliferative advantage in more-differentiated cells. These data also reveal that CALR mutations skew differentiation towards myeloid progenitors-including megakaryocytic primingearly during haematopoiesis (Extended Data Fig. 6b ).
Cell identity and the effects of CALR mutations
GoT data further offer an opportunity for de novo discovery of differentially expressed genes, by examining wild-type versus mutant cells within the same subset of progenitors. Crucially, the wild-type cells serve as an ideal comparison set, because they share all potential environmental and patient-specific variables with the mutated cells. We identified 198 genes that were differentially expressed between mutant and wild-type MkPs (false-discovery-rate adjusted P < 0.1) (Fig. 3a,  Supplementary Table 3 ). Mutated MkPs upregulated HSPA5, which encodes BiP, a key player in protein quality control that modulates the activities of the three transmembrane transducers of the unfolded protein response (UPR): PERK, IRE1 and ATF6 27 . Consistently, CALR-mutant MkPs showed upregulation of UPR genes (adjusted P = 1.7 × 10 −8 ) and ATF6-mediated activation of chaperone genes (adjusted P = 0.03) (Fig. 3a, Supplementary Table 4 ), which provides direct in vivo validation of previous in vitro studies that have shown an increased UPR in CALR-mutated cells 28, 29 . The UPR in this context may signal endoplasmic-reticulum stress in response to misfolded proteins, as the chaperone activity of CALR may be compromised by the mutation 30, 31 . Notably, among 20 differentially expressed genes in mutant HSPCs, XBP1-an important regulator of the UPR-was upregulated in mutant cells, which suggests that UPR activation by Table 6 ). c, Cell-cycle module expression in HSPCs (n = 108 wild type versus n = 240 mutant) and MkPs (n = 25 wild type versus n = 276 mutant) from ET03 (Extended Data Fig. 6a) Table 6) . P values combined using Fisher's combined test with Benjamini-Hochberg adjustment. Key geneset enrichments are shown (hypergeometic test, Methods). c, Expression of genes upregulated in UPR branches in MkPs (n = 442 wild type versus n = 640 mutant) and HSPCs (n = 1,704 wild type versus n = 613 mutant) from samples ET01-ET05. P values from likelihood ratio tests of linear mixed model, with and without mutation status (Methods). ER, endoplasmic reticulum. d, Schematic of GoT applied to the XBP1 splice site. e, Left, local regression of total and spliced XBP1 (XBP1s) expression in progenitor cells from samples ET03 and ET04 (n = 1,308 wild type versus n = 1,514 mutant; shading denotes 95% confidence interval). Right, ratio of XBP1s to unspliced XBP1 (XBP1u) in MkPs (n = 115 wild type versus n = 248 mutant) and HSPCs (n = 489 wild type versus n = 302 mutant). f, Expression of NF-κB pathway and anti-apoptosis genes in HSPC1 (n = 116 wild type versus n = 27 mutant), HSPC2 (n = 365 wild type versus n = 53 mutant) and HSPC3 (n = 381 wild type versus n = 105 mutant) from sample ET01. P values for e, f are from a two-sided Wilcoxon rank-sum test.
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CALR mutations extends to uncommitted progenitors (Fig. 3b) . This is further supported by the upregulation of ATF6-target genes in mutant HSPCs, as compared to wild-type HSPCs 32 (Fig. 3c, Extended Data Fig. 7, Supplementary Table 2) .
The UPR has previously been demonstrated to be preferentially mediated in HSPCs through PERK (which results in enhanced apoptosis upon endoplasmic-reticulum stress); this helps to eliminate endoplasmic-reticulum-stressed cells from the HSC pool 33 . By contrast, committed progenitors have robust activity of the IRE1-XBP1 arm of the UPR, which promotes survival through endoplasmicreticulum-stress challenge 33 . We observed that in the specific context of endoplasmic-reticulum stress induced by CALR mutation, the PERK branch of the UPR was not enhanced 33 (Fig. 3c, Extended Data Fig. 7, Supplementary (Fig. 3d) , we further validated that CALR mutations induce the activation of the IRE1 branch of the UPR, by repurposing GoT to probe for the spliced region of XBP1 in single cells. CALR mutations robustly augmented the amount of XBP1s in MkPs (Fig. 3e) . CALR mutations also resulted in an increased XBP1s/XBP1u ratio in HSPCs, which indicates IRE1 activity (Fig. 3e) . These data thus suggest that, in the UPR induced by CALR mutations, IRE1 is activated in both HSPCs and MkPs, which skews stem and progenitor cells challenged by endoplasmic-reticulum stress towards survival.
Analysis of differential gene expression in HSPCs also revealed upregulation of the NF-κB pathway (adjusted P = 0.03), including upregulation of CXCL2 and NFKBIA (Fig. 3b, Supplementary Tables 3,  4) . Furthermore, upregulation of the NF-κB pathway gene set in mutant versus wild-type HSPCs was most notable in early uncommitted HSPCs (Fig. 3f, Supplementary Table 2 ). Mutant cells in this early HSPC subcluster also upregulated anti-apoptotic-related genes (Fig. 3f , Supplementary Table 2 ). As NF-κB pathway activation has previously been associated with anti-apoptotic effects 37 and HSC self-renewal 38 , our data thus point to another potential mechanism that links CALR mutation and HSC outgrowth.
IRE1-mediated UPR in CALR-mutated myelofibrosis
As a proportion of patients with CALR-mutated essential thrombocythaemia eventually progress to myelofibrosis (or present initially with myelofibrosis), we examined whether CALR mutations impart a similar proliferative and survival advantage to progenitor cells from patients with CALR-mutated myelofibrosis, by examining 9,704 genotyped cells of 11,093 cells in total (87.5% genotyping rate) across four samples of myelofibrosis (Fig. 4a, b, Extended Data Fig. 8a ). In contrast to essential thrombocythaemia, we did not observe enrichment of mutated cells in differentiated progenitors compared to HSPCs (Fig. 4c , Extended Data Fig. 8b ), consistent with previous reports 39 . This suggests that, in the context of myelofibrosis, CALR mutations impart a strong fitness advantage even to HSPCs. Indeed, mutant cells were highly enriched in cell-cycle activity (Fig. 4d, Extended Data Fig. 8c ).
As megakaryocytes have previously been demonstrated to have a principal role in the development of marrow fibrosis 40 , we performed differential expression analysis between mutant and wild-type MkPs, which showed 92 differentially expressed genes (false-discovery-rate adjusted P < 0.1) (Fig. 4e, Supplementary Table 3) . We identified the upregulation of TGFB1, which has previously been implicated in fibroblast stimulation by megakaryocytes 41, 42 , and thereby demonstrated that TGFβ production is dysregulated even in early progenitors. The upregulation of TGFβ signalling in mutant MkPs correlated with the degree of fibrosis in the bone marrow of the patient (Extended Data Fig. 8d ). As in CALR-mutated essential thrombocythaemia, we observed a robust upregulation of UPR genes in mutated MkPs (adjusted P = 4.7 × 10 −7
) and, specifically, IRE1 activation (adjusted P = 0.0017) (Fig. 4e, Supplementary Table 4) . Notably, a comparison between cycling and non-cycling wild-type cells did not show upregulation of the UPR, which affirms that activation of the UPR is not simply a byproduct of increased proliferation (Extended Data Fig. 8e , Supplementary Tables 3, 4). These findings suggest that the increased survival of CALR-mutant progenitors through the upregulation of the IRE1-mediated UPR is maintained through disease progression to myelofibrosis.
Multiplexed GoT for subclonal identities
Ongoing clonal evolution results in multi-clonal malignant populations, which require genotyping of multiple mutations in parallel. To test the ability of GoT to target multiple mutations, we targeted three mutations that affect CALR (VAF 43.5% by bulk exon sequencing), NFE2 (VAF 33%) and SF3B1 (VAF 47.5%) in 8,475 CD34 + cells from a patient with myelofibrosis (Fig. 5a ). The relative VAFs of these mutations suggest that this malignancy follows a nested (linear evolution) clonal structure, with a clonal SF3B1 mutation and a progeny subclone containing a CALR mutation, which-in turn-has additional NFE2-mutated progeny (single-cell cloning validation in Extended Data Fig. 9a ). GoT provided genotyping for CALR and NFE2 in 74% and 60% of cells, respectively, and showed mutant frequencies (of 64% and 56%, respectively) comparable to those of single-cell cloning (85% and 71%, respectively, performed with unsorted peripheral blood cells).
In this context, GoT allows us to compare the transcriptional outputs of the different mutations alone, or in combination. For example, because SF3B1 mutations have previously been shown to block erythroid maturation 43 , we examined whether the addition of a CALR mutation would still confer increased proliferative status in megakaryocytic-erythroid progenitors. We found that the SF3B1 CALR double mutants exhibited an increased proliferative advantage over SF3B1 single mutants (Fig. 5b) , whereas the addition of NFE2 mutation Article reSeArcH (that is, the triple mutant) did not further increase cell-cycle activation. Thus, multiplexed GoT demonstrates the ability to examine complex clonal structures, as well as the need to assess the combinatorial transcriptional output of mutations in the context of the high-resolution mapping of cell identity.
Circularization GoT targets distant loci
GoT amplicon recovery is not only dependent on the expression level of the gene but also on the distance of the mutation locus from transcript ends (Extended Data Fig. 9b ). Capture efficiency of a mutation that is distant from the 3′ end (>1.5 kb) (for example, SF3B1 genotyping of 9% of cells, see Fig. 5a ) was lower than for targets closer to the 3′ end. Although driver mutations are often found within 1.5 kb of one of the transcript ends (Extended Data Fig. 9c ), loci of interest may reside at larger distances-and thus the dependency on relative proximity to transcript ends is limiting. We reasoned that the lower genotyping efficiency resulted at least in part from the inability of larger amplicon fragments to cluster efficiently on Illumina flow cells during sequencing. We further integrated our protocol with long-read sequencing using nanopore GridION X5 (Oxford Nanopore Technology), which demonstrated that SF3B1 transcripts were captured accurately with our procedure (Extended Data Fig. 9d , e) and further confirmed low intraand inter-transcript PCR recombination rate, even for these relatively large fragments (Extended Data Fig. 9f, g ).
To overcome the limitation of amplicon fragment length, we applied sequential rounds of circularization and inverse PCR to remove the intervening sequence between the region of interest and the cell barcode, resulting in a fragment length compatible with short-read sequencing (Fig. 5c) . Circularization GoT showed a high concordance with un-circularized GoT (that is, the standard linear GoT technique) for CALR genotyping (Extended Data Fig. 9h, i ). When applied to the capture of SF3B1 mutations, circularization GoT markedly increased the yield of genotyped cells from 750 to 2,004 cells (9% to 24% of cells) ( Fig. 5d, e ). These results demonstrate the ability of circularization GoT to extend our reach to targets that are distant from gene ends.
To further demonstrate the ability of circularization GoT to genotype efficiently even when mutations are at a considerable distance from a transcript end, we targeted JAK2 V617F (which is located about 2.3 kb from the closer transcript end). We first validated circularization GoT for JAK2 via a mixing experiment using barcoded cDNA from the TF1 cell line (wild-type JAK2) and from HEL cells (homozygous JAK2 V617F ), which showed accurate genotype assignment (Fig. 5f ). Next, we genotyped primary CD34
+ cells from an individual with JAK2 V617F essential thrombocythaemia, and obtained genotyping information for 7.3% of cells ( Fig. 5g ) even for this gene, which is expressed at very low levels. Mutant-cell frequency was higher in MkPs than in HSPCs, whereas the mutant-cell frequency remained low in erythroid progenitors (Fig. 5h) . This is concordant with the clinical phenotype of essential thrombocythaemia rather than polycythaemia vera (a disease that is associated with the same JAK2 mutation, but which is characterized by erythrocytosis as the leading abnormality). Consistent with this observation, we observed a trend towards increased MkP priming in mutant HSPCs (P = 0.04, Wilcoxon rank-sum) (Fig. 5i , Supplementary Table 2)-albeit in a small number of genotyped HSPCs. These data suggest a skewing of differentiation towards megakaryopoiesis in HSPCs and may provide insights into the isolated megakaryocytic proliferation in JAK2-mutated essential thrombocythaemia.
Discussion
Here we present GoT, which captures both somatic genotypes and transcriptomic identities in thousands of single cells from primary cancer specimens. Building on previous experience with targeted amplification in droplet-based scRNA-seq 44, 45 , GoT overcomes the unique set of challenges presented by the genotyping of somatic mutations, including lower expression levels and large distances from the end of the sequenced transcripts.
GoT allowed us to directly investigate the transcriptional effect of CALR mutations in primary samples of myeloproliferative neoplasm, in which wild-type cells in the sample provide an ideal comparison set that controls for patient-specific and technical confounders. In essential thrombocythaemia, we observed that mutant CALR provided a greater fitness advantage through differentiation, which was associated with higher proliferation in committed myeloid progenitors than in uncommitted HSPCs. The ability of GoT to finely map transcriptional differences between mutant and wild-type HSPCs revealed an upregulation of NF-κB pathway genes in the most-undifferentiated mutant HSPCs, which supports a cell-intrinsic role for CALR mutation in NF-κB activation 46 . We further applied GoT to target the unconventional splice 
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site of XBP1 to demonstrate that IRE1 activity was increased in the mutant cells, including HSPCs. Our data thus indicate that the IRE1-XBP1 pathway is a potential therapeutic target for the eradication of the mutant clone in uncommitted HSPCs in patients with CALR-mutated myeloproliferative neoplasms.
In conclusion, high-throughput linking of single-cell genotypic and transcriptomic data underscored the dependency of somatic mutations on cell identity in human haematopoiesis, and enabled us to superimpose the native differentiation tree with a tree corrupted by somatic mutations. GoT further provides a means to gain insight into the integration of clonal diversification with lineage plasticity 47 or differentiation topologies 48 across cancer. Thus, GoT may pave the way to resolving central questions related to the link between genetic mutations and cellular identities, and help to unravel the underlying programs that enable clonal expansions and evolution in human neoplasms.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41586-019-1367-0. . In brief, human MPL-expressing Ba/F3 and UT7 cell lines were generated by retroviral transduction, after which they were subjected to infection with CALR variant lentiviral supernatants. Wild-type UT7 cells and mutant Ba/F3 cells were mixed in equal proportions and underwent GoT, targeting ~1,000 cells. Although UT7 has been listed as a commonly misidentified cell line, it was used for the sole purpose of validating the CALR mutation status of the cells. All cell lines used in the study were tested for mycoplasma contamination. Patient samples. The study was approved by the local ethics committee and by the Institutional Review Board of Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, and conducted in accordance with the Declaration of Helsinki protocol. All patients provided informed consent. Cryo-preserved bone marrow mononuclear cells or peripheral blood mononuclear cells from patients with documented CALR mutations were retrieved after a database search (see Supplementary Table 1 for clinical information). Cryopreserved bone marrow mononuclear cells or peripheral blood mononuclear cells were thawed and stained using standard procedures (10 min, 4 °C) with the surface antibody CD34-PEVio770 (clone AC136, lot no. 5180718070, dilution 1:50, Miltenyi Biotec) and DAPI (Sigma-Aldrich). Cells were then sorted for DAPI KIT, KRAS, MPL, NFE2, NOTCH1, NPM1, NRAS, PHF6, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, SUZ12, TET2, TP53, U2AF1 and ZRSR2) that are recurrently mutated in myeloid malignancies was performed using the Thunderstorm system (Raindance Technologies) with a custom primer panel followed by sequencing using the Illumina MiSeq (v.3 chemistry). GoT. Extending recent experience with targeted amplicon sequencing in scRNAseq 44, 45 , we developed GoT to simultaneously capture genotyping data and whole transcriptomic data in single cells by adapting the 10x Genomics platform. The standard 10x Genomics Chromium 3′ (v.2 or v.3 chemistry) and 5′ libraries were carried out according to the manufacturer's recommendations until after emulsion breakage and recovery of first strand cDNA (Fig. 1a, step 1) . For 3′ libraries, if the targeted gene of interest (for example, SF3B1) was not robustly detected by the standard 10x procedure (that is, if <60% of the expected cells showed expression), on the basis of a priori knowledge in a similar dataset a gene-specific primer was spiked into 10x primer mix at 1% of the concentration of the cDNA amplification primers for the initial cDNA PCR step ( Fig. 1a; see Supplementary Table 5 for list of primers and Extended Data Fig. 1b, c for primer positions) . For 5′ libraries, the presence of 10x cell barcodes and UMIs on the 3′ side of the transcript enabled a gene-specific primer spike-in during the reverse transcription (RT) step (guide RT primer, 0.12 μM final concentration, Supplementary Table 5) to increase capture and detection of the transcript of interest (for example, JAK2). At the cDNA amplification step, another spike-in primer (additive primer) is added to increase the yield of the same transcript. During the amplification step, for 3′ libraries v.2 chemistry only, the 10x cDNA library underwent an extra cycle of PCR beyond the manufacturer's recommended number of cycles. (3′ v.3 chemistry and 5′ libraries do not require extra cycles of PCR at the amplification step.) After cDNA amplification and clean-up with SPRIselect, a small portion of the cDNA library (3 μl for 3′ v.2 and 10 μl for 3′ v.3 chemistry and 5′ libraries) was aliquoted for targeted genotyping, and the remaining cDNA underwent the standard 10x protocol. In the case of 3′ v.2 chemistry, the cDNA set aside for GoT was amplified for 3 to 4 additional cycles using KAPA HiFi HotStart ReadyMix (KAPABiosystems) and 10x primer mix to provide sufficient material for the enrichment step. After clean-up, locus-specific reverse primers and generic forward sample index (SI)-PCR oligonucleotide (10x Genomics) were used to amplify the site of interest of the cDNA template (Extended Data Fig. 1b, c, Supplementary Table 5 ). The number of PCR cycles was determined experimentally and was dependent on the level of expression of the targeted gene (for example, ten cycles were used for CALR). The locus-specific reverse primers contain a partial Illumina read 2 handle, a stagger to increase the complexity of the library for optimal sequencing and a genespecific region to enable specific priming. The SI-PCR oligonucleotide anneals to the partial Illumina read 1 sequence at the 3′ or 5′ end of the molecule when using 3′ or 5′ libraries, respectively, which preserves the cell barcode and UMI (Extended Data Fig. 1b, c) . After the initial amplification and solid phase reversible immobilization (SPRI) purification to remove unincorporated primers, a second PCR was performed with a generic forward PCR primer (P5_generic) to retain the cell barcode and UMI, together with an RPI-x primer (Illumina) to complete the P7 end of the library and add a sample index. The targeted amplicon library was subsequently spiked into the remainder of the 10x library to be sequenced together on a HiSeq 2500 or sequenced separately on MiSeq (Illumina). The cycle settings were as follows: 26 cycles for read 1, 98 or 130 cycles for read 2, and 8 cycles for sample index for 3′ v.2 chemistry and 5′ libraries; or 28 cycles for read 1, 98 or 130 cycles for read 2, and 8 cycles for sample index for 3′ v.3 chemistry. Circularization GoT. For patient samples, we used the same starting material as for GoT (that is, non-fragmented 10x cDNA fraction); for the JAK2 cDNA mixing study, we mixed barcoded cDNA from two cell lines (TF-1, JAK2 wild type (ATCC CRL-2003); HEL, homozygous JAK2 V617F (ATCC TIB-180). With these cDNA libraries, we first performed a PCR to enrich for the amplicon, amplifying from about 50 bp upstream of our region of interest to the 3′ end of the 10x library fragment (therefore retaining the cell barcode and UMI), using KAPA HiFi Uracil+ master mix (Kapa Biosystems) and the following PCR conditions: 98 °C for 3 min; 10 to 20 cycles of 98 °C for 20 s, 65 °C for 30 s, 72 °C for 2 min and 72 °C for 5 min. Complementary U-overhang are added to the forward (Fw) and reverse (Rv) primers to allow circularization: Fw-primer no. 1: AGGUCAGTCU-[specific to approximately 50 bp upstream of the locus], Rv-primer no. 1: AGACUGACCUCTACACGACGCTCTTCCGATCT (Extended Data Fig. 1b , c, Supplementary Table 5 ). For genes that are represented at low levels in the cDNA library (such as SF3B1), we specifically pre-enriched the gene of interest by doing a PCR that targeted about 100 bp upstream of our region of interest to the 3′ end of the 10x library fragment, using KAPA HiFi Ready mix (Kapa Biosystems) and the following PCR conditions: 95 °C for 3 min; 20 cycles of 98 °C for 20 s, 65 °C for 30 s, 72 °C for 2 min and 72 °C for 5 min. PCR product resulting from the first single or double PCR was then cleaned up and concentrated using 1.3× SPRI beads. Next, amplicon cohesive ends were created using 40 U/ml USERII enzyme (M5508-NEB) digestion for 1 h at 37 °C in 1× CutSmart buffer. Reaction was stopped by incubating for 10 min at 65 °C. Relying on complementary overhangs at both ends of the amplicon, circularization was performed in a large volume (>1 ml) to favour intra-molecule ligation. The following reaction was set up and incubated overnight at 16 °C: USERII-digested amplicon, 2,000 U/ml T4 ligase (NEB), 1× CutSmart Buffer (NEB) and 1 mM ATP (Roche). Next, T4 DNA ligase was inactivated by incubating for 15 min at 70 °C. Then, unwanted unligated products were removed by adding 6 U of lambda exonuclease (NEB, M0262S) in the ligation mix and incubating for 30 min at 37 °C. Exonuclease was inactivated for 20 min at 65 °C. Ligated product was cleaned up and concentrated using 1.3× SPRI beads. A second PCR was set up to retain the locus of interest and barcodes on the same molecule, while removing the unwanted 3′ downstream region of the targeted region. PCR reaction was set up and performed as previously described, using the following primers: Fw-primer no. 2: AGGUCAGTCU-[specific to 3′ end locus], Rv-primer no. 2: AGACUGACCU-[specific to 10 bp downstream of locus].
After PCR no. 2, SPRI clean-up, USERII digestion, overnight T4 ligation and lambda exonuclease digestion were performed as described above. After the second ligation, the ligated product was again cleaned up and concentrated using 1.3× SPRI beads. To increase ligation efficiency during the circularization step and to reduce protocol duration (from 3 days to 1 day), we further improved ligation by using the Gibson assembly molecular cloning approach. Instead of U-overhang handles, complementary Gibson handles are added to the forward and reverse primers to allow circularization after PCR no. 1 and PCR no. 2 (Extended Data  Fig. 1b, c, Supplementary Table 5 ). PCR no. 1 and PCR no. 2 are performed as described above for the U-overhang version of this protocol, but using KAPA HiFi Ready mix. Ligation was then performed over 1 h at 50 °C in a large volume (>1 ml, 1× CutSmart Buffer) and using 10 μl of Gibson master mix (NEB, E2611). Finally, to linearize the product of ligation, we performed a third PCR: Fw-primer no. 3: CCTTGGCACCCGAGAATTCCA-[specific to 10 bp upstream of the locus] Rv-primer no. 3: SI-PCR (10x Genomics). We used KAPA HiFi master mix (Kapa Biosystems) and the following PCR conditions: 95 °C for 3 min; 10 cycles of 98 °C for 20 s, 65 °C for 30 s and 72 °C for 30 s; 72 °C for 5 min. After SPRI purification, a final PCR was performed with a generic forward PCR primer (P5_generic) and an RPI-x primer (Illumina) to complete the P7 end of the library and add a sample index (95 °C for 3 min; 5 cycles of 98 °C for 20 s, 67 °C for 30 s and 72 °C for 30 s; 72 °C for 5 min). This method generates amplicons that retain the contiguity of the original molecules but are short enough to cluster effectively to be sequenced with standard parameters. The targeted amplicon library was subsequently sequenced using PE150 on MiSeq (Illumina). scRNA-seq data processing, alignment, cell-type classification and clustering. 10x data were processed using Cell Ranger 2.1.0 with default parameters. Reads Article reSeArcH were aligned to the human reference sequence GRCh38 or hg19, or to mouse reference mm10 (species-mixing experiment). The genomic region of interest for genotyping was examined to determine how many UMIs with the targeted sequence were present in the conventional 10x data (Fig. 1c, Extended Data Fig. 3a, b) .
The Seurat package (v.3.0) was used to perform unbiased clustering of the CD34 + sorted cells from patient samples 18, 50 . In brief, for individual datasets, cells with UMI < 200 or UMI > 3 s.d. from the mean UMI, and mitochondrial gene percentage > 10%, were filtered. The data were log-normalized using a scale factor of 10,000. Before clustering, the essential thrombocythaemia and myelofibrosis datasets were integrated and underwent batch-correction within Seurat, which implements canonical correlation analysis and the principles of mutual nearest neighbour. Recommended settings were used for the integration (30 canonical correlation vectors for canonical correlation analysis in the FindIntegrationAnchors function and 30 principal components for the anchor weighting procedure in IntegrateData function). For the datasets, potential confounders (for example, numbers of UMI per cell and the proportion of mitochondrial genes) were regressed out of the data before principal component analysis was performed using variable genes. The JackStraw method was used to determine the statistically significant principal components to be used for graph-based clustering. t-SNE was used to visualize the clusters. Clusters were manually assigned on the basis of differentially expressed genes using the FindAllMarkers function using default settings (using all genes that are detected in a minimum of 25% of cells in either of the 2 comparison sets as input, and log-transformed fold change of 0.25 as the threshold). Wilcoxon rank-sum test was applied to rank genes, with the top 10 differentially expressed genes per cluster presented in Extended Data Fig. 4b . We identified 19 distinct clusters in the integrated data for samples ET01-ET05, which were annotated according to previously identified marker genes 26 (t-SNE in Fig. 1d , and clustering heat map and t-SNE with representative marker genes in Extended Data Fig. 4b, c) . Pseudotime analysis was performed using the Monocle R package (v.3.8) for individual datasets 20 and the URD package (v.1.0.2) for the integrated datasets 21 . Linear mixed effects analysis was performed using the lme4 package (v.1.2-1). For mutant-frequency analysis between HSPCs and MkPs (Fig. 1g) , genotype status was defined as the fixed effect, and as random effects we used intercepts for individual patients (subjects) and iterative downsampling. For integrated analysis of pseudotime comparisons (Fig. 1i) and gene-module expression (for example, Fig. 3c ), genotype status was entered as the fixed effect and subjects as random effects. P values were obtained by likelihood ratio tests of the full model with the fixed effect against the model without the fixed effect 51 . IronThrone GoT for processing targeted amplicon sequences and mutation calling. To ensure correct priming, targeted amplicon reads (read 2) were screened for the presence of the primer sequence and the expected intervening sequence between the primer and the start of the mutation site ('shared sequence'; for circularization GoT, PCR no. 2 forward and PCR no. 2 reverse primer sequences) (Extended Data Fig. 2a, b) . Ninety per cent of the reads from the mixing study showed the expected primer and shared sequences. Subsequently, for reads that passed the priming step, the corresponding read 1 was screened for the presence of the 16-bp-or 18-bp-long cell barcode that matched the cell barcode in the whitelist provided by 10x Genomics (Extended Data Fig. 10 ). For cell barcode reads that were one Hamming distance away from the whitelisted cell barcodes, the probability that the observed barcode originated from the whitelisted cell barcode was calculated, taking into account the base quality score at the differing base. The whitelisted cell barcode with the highest probability was used to replace the observed cell barcode only if the probability exceeded 0.99. For the duplicate reads with the same cell barcode and UMI, the genotype (wild type versus mutant) of the UMI was assigned on the basis of majority rule in supporting reads, or according to the read with the highest base quality score (in the rare cases in which only two supporting, but discordant, reads were available).
The species-mixing study for CALR (type 1) mutation was used to further optimize the analytical assignment of genotypes to cells, to overcome technical sources of noise such as PCR errors, ambient mRNA and PCR recombination, which may accompany targeted amplification in scRNA-seq. A mean ( ± s.d.) of 83.6 ( ± 95.3) CALR UMIs were detected per cell in the amplicon data, with 52 (± 16.3) reads per UMI. We integrated targeted amplicon measures including base quality, number of base pair mismatches and number of duplicate reads per UMI, and determined optimized parameters that maximize the number of genotyped cells and minimize genotype misassignment (Extended Data Fig. 2c-g ). Setting thresholds for the minimum number of duplicate reads and maximum frequency of mismatches contributed substantially to filtering out misassigned reads that were probably due to technical errors (such as PCR recombinations). A combination of a threshold of 2 or more duplicate reads for a given UMI and a threshold of allowing less than or equal to 0.2 mismatch ratio improved correct assignment of cells, and maximized the number of included cells for analysis, and was adopted in the analysis here (Extended Data Fig. 2c) . Results of the precision and recall analyses also affirmed this combination of thresholds for minimum duplicate reads and maximum mismatch ratio (Extended Data Fig. 2d) . Moreover, given the high number of CALR transcripts in the cell lines and thus higher potential effect of PCR recombination, cells were assigned as wild type or mutant if >90% of CALR amplicon UMIs were wild type or mutant, respectively.
To further assess the effect of various parameters of the amplicon reads on the precision of mutation calling, we tested these parameters in a random-forest classification using the mixing study, as implemented in the R randomForest package (v. 4.6-14) 52 (Extended Data Fig. 2e-g ). Mean decrease accuracy was determined as a measure of importance of each variable used for the calculation of splits in trees (Extended Data  Fig. 2e ). For each combination of mismatch ratio and duplicate thresholds, the random forest was run 100 times to find the optimal number of random variables used in each tree and the minimum out-of-bag error was selected (Extended Data Fig. 2f,  g ). This random-forest analysis also showed a minimum duplicate read threshold of 2 and maximum mismatch ratio threshold of 0.2 to be optimal for minimizing misassignments, and a relatively low contribution of additional quality metrics.
Moreover, the genotyping information is derived from transcribed molecules and may be affected by the capture of transcripts from wild-type and mutant alleles of heterozygous mutations in primary patient samples (in which the median targeted amplicon UMI count per cell was 5 (±4.45, median absolute deviation)). This may be due to incomplete sampling of the transcript pool or to transcriptional bursts 53 , which leads to skewed transcript pools. Consequently, as the number of UMIs per cell increases, the likelihood of capturing a mutant transcript increases, which results in an apparently higher frequency of mutant cells. Thus, the number of mutant reads may be underestimated in cells with lower amplicon UMI counts. Nonetheless, the frequency of mutant cells (for example, 26% in sample ET01) as determined by GoT using all cells that contain at least one UMI yielded values that were similar to that determined by bulk DNA exon sequencing of CALR from CD34
+ cells (mutant-cell fraction of 30%, based on VAF of 0.15 in a diploid heterozygous mutation). Although the bulk of the downstream analyses between CALR mutant and wild-type cells used a threshold of two or greater genotyping amplicon UMIs, we systematically applied three approaches to exclude the effect of this confounder (that is, the expression level of the target gene) on the conclusions. First, to exclude the possibility that higher CALR expression in committed progenitors results in a greater ability to detect mutant alleles, and thereby in a higher mutant-cell frequency, we downsampled all cells to a single amplicon UMI before mutation calling and found that the increase in mutation frequencies in MkP compared with HSPC remained unchanged (Fig. 1f, g ). Second, we explored the sensitivity of the difference between mutant and wild-type cells (for example, pseudotime or mutant-cell frequency) by increasing the minimal amplicon UMI threshold allowed for mutation calling, and demonstrated that this did not effect the central findings of this study (Extended Data Fig. 5a, b) . Third, we explicitly modelled the effect of CALR amplicon UMI in multivariable models (generalized linear model using R statistics package v.3.5.1 (for example, pseudotime analysis)), in which the number of amplicon UMIs was included in the model alongside the mutation status (Extended Data Fig. 5c ). We further note that the GoT procedure did not result in loss of genes or UMIs per cell in comparison to published data of CD34 + selected cells from the standard 10x library 54 (Extended Data Fig. 3d ). For XBP1 splicing analyses, we required a cell to have at least one unspliced XBP1 for inclusion in the analyses. Deep generative model for single-cell analysis. We applied a previously published 19 deep generative modelling approach for the single-cell analysis of samples ET01-ET05 19 (Extended Data Fig. 4d, e) . Using the scVI package, we trained a variational auto-encoder that takes as input a feature vector for each cell, consisting of transcript counts for the 256 genes with the highest s.d. across all samples as well as an indicator for batch identity. Using 90% of cells for training and holding back 10% for validation, these features are provided to the variational auto-encoder with 64-unit hidden layers in both the encoder and decoder modules, and a fourdimensional internal latent vector of Gaussian-distributed values that provide a more concise representation of biological variability between cells. t-SNE is applied to these vectors for visualization. Analysis of mutant-cell frequency. For integrated analysis of samples ET01-ET05 or MF01-MF04, an equal number of cells from each sample (n = 900 for essential thrombocythaemia and n = 400 for myelofibrosis) were subsampled randomly. Genotyping amplicon UMIs were downsampled (×100 iterations) to one per cell and mutant-cell frequency was determined for each cluster for either the integrated dataset or individual samples. This frequency was then divided by the total mutantcell frequency across all progenitor subsets for each of the iterations (Figs. 1f, g, 4c , 5h, Extended Data Fig. 5d ). Differential expression and gene-set enrichment analysis. For gene-module analysis, the aggregate gene-expression levels of modules of genes that are involved in biological processes of interest (see complete list of genes for each module in Supplementary Table 2) were calculated as log 2 of the ratio of UMIs in the gene module per 10,000 UMIs per cell. The gene modules have been previously published 22,24-26,32,33 (Supplementary Table 2 ). Differential gene-expression analysis between mutant and wild-type cells for each of the progenitor clusters for each patient was performed via the FindMarkers function within the Seurat package Article reSeArcH using the logistic regression for differential gene expression 55 , with variable genes as input and requiring expression in at least 10% of cells in either group. UMI was included as a latent variable. The differentially expressed genes were examined individually for each patient; they were also examined in combination for each cluster across the patients by combining the P values for the differentially expressed genes using Fisher's method, and performing a weighted average of the log 2 -transformed fold change (Supplementary Table 3 ). Genes that were differentially expressed with false discovery rate < 0.1 and log 2 -transformed fold change ≥ 0.2 were included for gene-set enrichment analysis. Hypergeometric test for gene-set enrichment analysis was performed using the gProfileR package (v.0.6.7) 56 . Multiple hypothesis testing correction was performed using the g:SCS algorithm, developed by the authors of the gProfileR package. Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, GO:MF and GO:BP data sources were included in the analyses (Supplementary Table 4) . Comparison of mutant allelic fraction in whole-exome sequencing and RNA-seq. We compared the mutant allelic fractions between genomic DNA and RNA-estimated from whole-exome sequencing (WES) and RNA-seq data, respectively-in five cancer cohorts (breast invasive carcinoma, head and neck squamous cell carcinoma, kidney renal clear cell carcinoma, lung adenocarcinoma and stomach adenocarcinoma). For this analysis, we thank T.-M. Kim (Cancer Research Institute, College of Medicine, The Catholic University of Korea) for sharing the datasets curated for a previous study 57 . In brief, the datasets of each of the cancer cohorts were initially prepared with somatic mutation sets from The Cancer Genome Atlas portal (https://portal.gdc.cancer.gov/). Then, reference and alternative alleles for these mutations were counted in .bam files of WES and RNA-seq using SAMtools mpileup 58 , and filtered for >10 coverage of reads. We then converted genomic coordinates of the datasets from hg19 to hg38 assembly. We identified the frequencies of somatic mutations in cancer samples from CosmicCodingMuts.vcf (v.86) , using previously published definitions.
Determination of distance of targeted loci from 3′ or 5′ ends of transcripts.
To identify Ensembl transcript identifiers that correspond to each mutation in the datasets of the five cancer cohorts described above, we matched them with COSMIC identifiers and annotated from the file of CosmicMutantExport.tsv (v.86). We used the biomaRt R package 62 with the GRCh38 version to annotate the transcript, including the length of transcript and the position of cDNA start codon in the transcript. The positions of the 5′ untranslated region ends were determined to calculate the distance from 5′ end to target site. Oxford Nanopore Technology. The cDNA amplicon samples were barcoded by ONT 1D native barcoding kit EXP-NBD104. The barcoded samples were fed into the ONT SQK-LSK109 library preparation and sequencing workflow. FLO-MIN106 RevD flowcells and GridION X5 sequencer were used for sequencing. Data were base-called by ONT Guppy 2.3.1. For analysis, the adaptor sequences were trimmed using Porechop (https://github.com/rrwick/Porechop). Then, the reads were assessed for correct priming as shown in Extended Data Fig. 9d . The correctly primed reads were aligned to the reference genome (Grch38) with minimap2 63 (v.2.16) for variant calling. The cell barcodes underwent the same processing as described above for IronThrone GoT (Extended Data Figs. 9d, 10) . ddPCR. Peripheral blood from three patients with essential thrombocythaemia with mutations in CALR underwent Ficoll density gradient separation, immunomagnetic selection for CD34 + cells (Miltenyi Biotech) and FACS (Influx, Becton Dickinson) using PeCy7-labelled CD34, clone 561 (lot no. B257238, BioLegend), APC-labelled CD38, clone HIT2 (lot no. B247250, BioLegend) and FITC-labelled CD10, clone HI10a (lot no. B254556, BioLegend) antibodies were used to isolate CD34
+ and CD34 + CD10 + cell compartments. DNA was extracted from sorted cells (Qiagen) and the VAF of CALR mutations was measured by ddPCR (QX200 Droplet Digital PCR System, Bio-Rad) with primers that specifically detect CALR type 1 mutations (52-bp deletion (p.L367fs * 46), CALR type 2 mutations (5-bp TTGTC insertion (p.K385fs * 47) or wild-type alleles. Single-cell colony genotyping assay. Viably frozen mononuclear cells were thawed and plated in H4434 Methocultä medium (StemCell Technologies) containing recombinant human SCF, GM-CSF, IL-3 and EPO according to the manufacturer's specifications. Individual colonies (n = 94) were picked from the methylcellulose medium after 14 days of culture at 37 °C and sequenced by Sanger sequencing for SF3B1, CALR and NFE2 mutations using primers listed in Supplementary Table 5 . Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
All of the sequencing data are available via the Gene Expression Omnibus (GEO) under the accession number GSE117826. Any other relevant data are available from the corresponding author upon reasonable request.
Code availability
The IronThrone GoT pipeline is available on GitHub at https://github.com/landau-lab/IronThrone-GoT. Among candidate CBs which are 1-Hamming-distance away from the whitelisted CB, compute the probability that the observed CB deviated from the whitelisted CB due to a sequencing error at the differing base, and replace the observed CB with whitelisted CB when the probability exceeds 0.99 
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, t-SNE projection of CD34
+ progenitor cells from samples ET01-ET05, after integration and batch correction using the Seurat package (Methods). b, Heat map of top ten differentially expressed genes for clusters; lineagespecific genes from a previous publication 26 are highlighted (Methods). c, Representative lineage-specific genes projected onto the t-SNE representation of CD34 + cells from samples from patients with essential thrombocythaemia. d, t-SNE projection of CD34 + cells from samples ET01-ET05 after applying a deep generative modelling approach for the single-cell analysis using the scVI package (Methods) 19 , showing assignments of progenitor subsets as determined after clustering the cells using the Seurat package. e, Genotyping data from GoT are projected onto the t-SNE representation generated after the scVI analysis of progenitor cells from samples ET01-ET05. Cells without any GoT data are labelled NA (not assignable). (n = 240)(n = 268) P < 10 -10 P < 1.3 x 10 -8 P < 2.3 x 10 -7 P < 0.018 P < 0.0093 P < 0.12 P < 10 -10 P < 10 -10 P < 1.5 x 10 -9 P < 10 -10 P < 10 -10 P < 9.1 x 10 -9 P < 2.6 x 10 -6 P < 0.001 P < 0.088 2 3 P = 6 x 10 -8 P = 9 x 10 -5 P = 0.059 P = 0.0017 P < 10 -10 P = 9 x 10 -5 P = 0.067 P = 0.0023 P < 10 -10 P < 10 -10 P < 10 -10 P < 10 -10 P < 10 -10 P = 5 x 10 -8 P = 0.02 P = 0.0019 P < 10 -10 P < 10 -10 P < 10 -10 P < 10 -10 Table 6 for sample size). b, Pseudotime comparison between wild-type and mutant cells with an increasing number of thresholds for targeted genotyping UMI (two-sided t-test; see Supplementary Table 6 for sample size). c, Pseudotime comparison between mutant and wild-type cells with UMI threshold of 1 (same datasets as b), with statistical test using a generalized linear model including mutation status and total number of amplicon UMIs per cell. d, Across 100 iterations, the genotyping amplicon UMIs were downsampled to one per cell and the mutant-cell frequency was determined for MkPs or precursor B cells. This frequency was then divided by the total mutant-cell frequency across all progenitor subsets for each of the 100 iterations. Mean ± s.d. after n = 100 downsampling iterations (two-sided Wilcoxon rank-sum test). Essential thrombocythaemia samples with at least 20 cells in each cluster were analysed. e, VAF of CALR mutation in CD34 + CD38 − (left), CD34 + CD38 + (middle) and CD34 + CD10 + (right) FACS-sorted peripheral blood cells from patients with essential thrombocythaemia determined by ddPCR. Table 6 for sample size). Analysis was performed for clusters with at least 20 cells. b, Ratio of committed-progenitor priming-module expression of mutant and wild-type HSPCs. One mutant and one wild-type HSPC were randomly sampled from samples ET01-ET05 for each round of analysis (n = 1,000 iterations, two-sided Wilcoxon rank-sum test). + progenitor cells from samples MF01-MF04, after integration and batch correction using the Seurat package (Methods) (n = 11,093). b, Left, t-SNE projection of CD34 + progenitor cells from samples MF01-MF04 labelled with pseuodotime 21 (n = 11,093). Right, pseudotime comparison between wild-type (n = 2,221) and mutant (n = 7,483) cells. P values from likelihood ratio tests of linear mixed model with genotype as fixed effect and individual patient samples as random effect, against the model without the genotype effect (Methods). c, Cellcycle module score comparison between wild-type and mutant cells in patients with myelofibrosis (two-sided Wilcoxon rank-sum test). d, Ratio of TGFβ-signalling-pathway gene expression of mutant and wild-type MkPs. One mutant and one wild-type MkP were randomly sampled for each round of analysis (n = 100 iterations; two-sided Wilcoxon-rank sum test). e, Differentially expressed genes between wild-type MkPs with high cell-cycle expression (n = 220) and wild-type MkPs with low cell-cycle expression (n = 110), common across samples MF02-MF04. P values were combined using Fisher's combined test with Benjamini-Hochberg adjustments. Weighted average of fold change (expressed in log 2 ) based on cell number across samples is shown (Methods).
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Article reSeArcH Mutations are annotated as oncogenes, tumour-suppressor genes or passengers (as previously defined 60, 61 ). Relative density of each subclass of mutations from the closer end (that is, 3′ or 5′) is shown in the top panel. d, Schematic of analysis of ONT sequencing reads. e, Frequency of SF3B1-mutant and wild-type reads of linear GoT amplicon library sequenced with ONT. f, Analysis of SF3B1 amplicon reads sequenced by ONT for inter-transcript PCR recombination by mapping 50 bp at the opposite end of the targeted locus, showing only the 2.2% of fragments that reflect inter-transcript recombination. g, Pairwise difference of read lengths for duplicate reads (that is, reads with the same cell barcode and UMI) of the SF3B1 amplicon library sequenced with ONT, showing consistent read lengths of duplicate reads that support a low rate of intratranscript PCR recombination. h, Comparison of genotype assignment for CALR in sample MF01 between linear GoT and circularization GoT after downsampling reads to 300,000 with 10 iterations (n = 320 cells). i, Comparison of CALR-mutant UMI fraction per cell in sample MF01 between linear GoT and circularization GoT after downsampling reads to 300,000 with 10 iterations (n = 320 cells, Pearson's correlation, F-test). Fraction of reads (%) n/a Confirmed
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Software and code
Policy information about availability of computer code
Data collection
No commercial, open source, or custom software or code was used for data collection.
Data analysis
Conventional 10x data was processed using Cell Ranger (ver.2.1.0). Amplicon data was processed using the in-house codes which are available upon request. Downstream analyses and statistical analyses were performed using Seurat (ver. 3.0), Monocle (ver. 2.8), URD (ver.1.0.2), randomForest (ver. 4.6-14), gProfileR (ver. 0.6.7), lme4 package (ver. 1.2-1), R Stats (v3.5.1) packages under R environment (ver. 3.4.3) or scVI under Python environment (ver. 3.7.2). ONT data were basecalled by ONT Guppy (ver. 2.3.1), adaptor sequences trimmed using Porechop, and aligned with minimap2 (ver. 2.16). The Cancer Genome Atlas (TCGA) was analyzed using SAMtools mpileup (ver. 1.9) and biomaRt R package (ver. 2.39.2).
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All the raw data used in this study has been deposited at Gene Expression Omnibus, under the accession number GSE117826
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Sample size
A total of 29,815 cells were included from ET (n = 5) and MF (n = 4) patients. This enabled comparison of mutant and wildtype cells within each patient sample within the context of cell identity; data from replicate patient samples confirmed the findings within each patient.
Data exclusions Based on the conventional practices of the scRNA-seq field set by the experts, we filtered out poor quality cells in 10x data analysis with following criteria: mitochondrial RNA fraction (>10%), minimal detected number of genes (<200), maximal detected number of genes (>mean +3*standard deviation across cells). In the amplicon data analysis, we applied specific thresholds (mismatch ratio <0.2, total number of duplicates >=2) based our experimental data (species-mixing study). Detailed methods for processing amplicon data are fully described in the online methods section and pipeline available on GitHub at https://github.com/thinktank-Q/IronThrone-GoT.
Replication
To verify the analyzed results, we have included five CALR+ ET and four CALR+ MF patient samples. The main findings of the study were reproduced in these replicate samples Randomization Since the analyses are based on comparison between mutant and wildtype cells within each patient samples, randomization was not relevant for this study.
Blinding
Since the analyses are based on comparison between mutant and wildtype cells within each patient samples, blinding was not relevant for this study.
Reporting for specific materials, systems and methods 
Antibodies
Antibodies used CD34-PE-Vio770 (clone AC136, lot #5180718070, Miltenyi Biotec) for GoT; CD34-PeCy7 (clone 561, lot #B257238, BioLegend), CD38-APC (clone HIT2, lot #B247250, BioLegend) and CD10-FITC (clone HI10a, lot#B254556, BioLegend) for ddPCR. The antibodies were diluted according to manufacturers' recommendations.
Validation
Negative control has been performed on every patient sample to properly set-up the gate of CD34, CD38, and CD10 positive cell
